The week in pharma: action, reaction and insight – week to April 28, 2023

30 April 2023

By Barbara Obstoj-Cardwell. Editor

Big pharma financials dominated the news last week, first among which were from Swiss pharma giant Novartis, whose first-quarter 2023 figures beat Wall Street expectations. Also, GSK released results, along with a promise to strengthen its pipeline. On the research front, Ionis and partner AstraZeneca reported positive Phase III data on their eplontersen in the treatment of polyneuropathy. Meantime, Nektar revealed that Eli Lilly had returned rights to the Lupus treatment rezpegaldesleukin (rezpeg).

Novartis stays focused

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK